Telix Files Form 20-F Registration Statement for Nasdaq ADS
October 17, 2024 17:28 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement...
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
October 17, 2024 03:31 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the...
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
October 04, 2024 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the...
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
October 03, 2024 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial...
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
September 22, 2024 18:59 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS...
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
September 17, 2024 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal...
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
September 10, 2024 18:38 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON1 trial have been...
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
September 03, 2024 18:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in...
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
August 27, 2024 19:12 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United...
Telix Announces Reorganisation to Deliver on Strategic Priorities
August 26, 2024 19:17 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation...